Bipolar disorder stories

Oct 20, 2026

Rapport Therapeutics' RAP-219 meets primary endpoint in phase 2 bipolar mania trial

Rapport Therapeutics announced positive phase 2 results for RAP-219, an oral AMPA receptor modulator licensed from Johnson & Johnson, showing improvement in bipolar mania symptoms. This marks the company's second phase 2 success for the asset in 14 months.

Oct 20, 20263 sources

Oct 18, 2026

GLP-1 drugs linked to lower kidney failure risk in bipolar disorder patients, Mayo Clinic study finds

Mayo Clinic researchers found that GLP-1 receptor agonists were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease. The medications, widely used for diabetes and weight management, showed potential kidney-protective benefits in this patient population.

Oct 18, 20262 sources